Capitalism at the cost of healthcare

November 20, 2026 - 14:40
 0  0
Capitalism at the cost of healthcare

The Supreme Court recently slammed the Union Government over steep mark-ups on essential medicines in India. The apex court bench comprising Justices Vikram Nath and Sandeep Mehta described such excessive hospital margins as “loot” and “dacoity”. The Court also questioned why the Union Government was reluctant to bring a wider range of medicines under price control. It observed that the Centre’s reliance on market forces and concerns regarding the growth of the pharma industry cannot justify leaving patients exposed to medicine prices that may be hundreds of times higher than the cost at which they were procured.

It is interesting to look at the arguments between the Court and the Union Government. The following are a few examples of these arguments, which reveal how casual and callous the government has been in taking action against firms and hospitals in this regard.

Supreme Court’s arguments

During the proceedings, the Supreme Court questioned the government’s approach towards medicine pricing and its emphasis on commerce and economic policy over the lives of citizens.

  • “You are talking only in the terms of commerce, economic policy, this is a matter in which economic policy will be supreme as compared to the life of the citizens at large?”
  • “You are dealing with the lives of people, Don’t take it as a commerce. Treat it as a life of the poorest person of this country.”
  • The bench also questioned the government’s reliance on innovation as a justification for allowing market forces to operate. A Justice asked, “to name a few molecules developed by the Indian Pharmaceutical industry in the preceding 30 years???”
  • “You at the initial level fix the MRP right up to the moon. Then you increase by 10%. How does that make a difference?”
  • He further questioned, “Your calibration is too wayward. Rs 11,000 to Rs 1,30,000 for cancer drug is no calibration… When you talk of patients and life, should we have such capitalistic thinking?”
  • Further, the Court sought to know whether these considerations justified MRPs hundreds of times higher than procurement prices in tenders.

Referring to the Centre’s recent decision in October 2026 to cap trade margins on anti-cancer drugs, the Court pointed out that the 30 per cent cap covered only a limited portion of the market, while nearly 90 per cent remained outside the price control mechanism.

The Court also questioned the government, asking, “Why is the DPCO not in place at all? Why the government is allowing this to happen. There have been three parliamentary committees on this. And their outcome is not very convenient to people who pull the strings.”

To put it succinctly, the Court has clearly concluded that there is a total failure on the part of regulatory control in two areas:

  1. Proper selection of medicines for price control.
  2. Fixing of MRP by the manufacturer.

The Court has also concluded that the reasons for this include a totally callous and casual attitude and a “not pro people but pro-industry approach” on the part of Indian regulatory authorities.

In this context, it is worthwhile to understand the world’s most successful National Health and Drug Policy of Norway.

National Health and Drug Policy of Norway – Role model for WHO

Basic concept – The Medical Need Clause: “Less is More” policy

This policy has been in place since 1938. In Norway, a new drug can only be registered if there is a “clear-cut medical need for any new product” and “new drugs should represent better therapeutic alternatives than those already on the market”.

This was called Behovsparagrafen – the Medical Need Clause (MNC). It still continues. The Director of Health could reject a drug even if it was approved in European countries such as the UK, France and Germany.

Although the industry describes this policy as a “dictatorship” model, it kept industry lobbying out.

Consequently, Norway had only around 1,800 drugs on the market, compared with more than 10,000 in Germany and France, which is ten times the number in Norway.

Salient features of Norway’s drug policy

  1. Essentiality: The selection of new drugs is based on “Public health need” and Health Technology Assessment, and not on the claims made by the industry.
  2. Changing disease burden: The selection changes as healthcare needs change. For example, initially the focus was on TB, while now it includes cancer and diabetes.
  3. Efficacy and safety: There must be unequivocal evidence regarding the quality of medicines, with global cGMP standards.
  4. Cost-effectiveness: The total treatment cost, and not just the unit price, is compared with the tender price.
  5. Strict FDC policy: Fixed-dose combinations (FDCs) are allowed only if they demonstrate a proven therapeutic advantage over a single drug. Combination drugs, for example antibiotics and vitamins, were rejected as “at best fraudulent and at worst dangerous”. FDCs of antimicrobials were kept off the market. Broad-spectrum antibiotics were viewed with suspicion from the late 1960s. That is why Norway still uses narrow-spectrum penicillin (phenoxymethyl-penicillin) as first-line treatment today and has the lowest antimicrobial resistance in Europe.

Thus, for its Essential Medicines Policy, Norway has one of the oldest and most unique price control mechanisms. It introduced one of the strictest models in the world. This model was praised by WHO as an ideal rational drug policy and became a role model for the WHO Essential Medicines List from 1977. The WHO Essential Drug concept was actually inspired by Norway.

Comparison – India vs Norway

India

India has some of the cheapest generics in the world and uses the WHO model of Essential Medicines. However, it separates the framework into two parts.

NLEM List: This is a list of essential medicines for public health, for which prices are controlled. However, availability is not controlled. As a result, many generic manufacturers stop manufacturing essential medicines because of low profit margins.

Ultimately, hospitals suffer because of the non-availability of life-saving medicines such as penicillins, tetracyclines, adrenaline and oxytocin.

In India, these medicines were once made available through government-run companies such as Hindustan Antibiotics, IDPL and Bengal Immunity, which are now non-functioning because of a lack of government support. Paradoxically, it is not surprising that the idle and unused space at IDPL is now used for the NPPA office.

Non-NLEM List: The philosophy followed since 1970 has been, “You can sell, we will not fix price but monitor”. The approach is to promote competition and let the market decide prices for non-essential medicines. The idea was that more brands would automatically lead to lower prices.

However, in practice, this created brand proliferation because non-scheduled pricing is loosely controlled.

With the result: Currently, there are only 935 scheduled formulations under ceiling price, covering 384 NLEM molecules, while a vast number of 85,000 to 100,000 formulations are actually in the market, often quoted at prices 60 to 100 times higher.

Norway

Norway does not separate medicines into NLEM and non-NLEM categories. The total number of medicines was only around 1,800 in the 1970s. Now, there are around 5,200 authorisations, but only around 1,200 to 1,500 are allowed for active marketing after tendering and substitution.

Price control is implemented through a national-level tendering system.

Norway follows the “Less is More” legacy. Until 1994, its law stated: “If there is already a drug that does same job, new one has NO medical need, it is, rejected”.

As a result, me-too drugs never entered the market. Even after 1994, the reimbursement rule states: “If we already have 3 ACE inhibitors, we will tender and only cheapest 1-2 will be reimbursed.” Therefore, effectively, all actively used drugs are under price control.

Secondly, Norway follows the WHO’s Aware antibiotic classification strictly. The goal is to achieve the lowest antibiotic resistance and high access with low spending.

India – Two gates: State and Central dual system

In India, CDSCO approves new drugs, but State FDA issues manufacturing licences.

Until 2022, states could approve generics without checking whether the same drug had already been approved centrally. As a result, the same molecule, such as paracetamol 650 mg, could receive licences in 28 states with 20 manufacturers in each state, resulting in 560 licences. Each could have a different brand name.

Data placed by DCGI in an affidavit in 2023 showed that there were more than 14,000 licences for paracetamol combinations.

Consequently, only 35 per cent of drugs are covered by public procurement through Jan Aushadhi and state medical corporations. The remaining 65 per cent is the private, out-of-pocket market, where the patient buys the brand prescribed by the doctor.

Therefore, price control is not on the MRP sticker.

Norway – One gate

Norway follows a single-agency system through NOMA. If EMA (European Medicines Agency) rejects a drug or NOMA says there is no therapeutic need, the drug cannot be sold anywhere in Norway. There is no state-level bypass.

Until 1994, the Medical Need Clause actively rejected all me-too drugs.

India – Quality of medicines

In India, all medicines are manufactured under the following two criteria:

  1. Three types of GMP (Good Manufacturing Practices):
  1. cGMP standards for marketing to developed countries such as the US and EU.
  2. WHO-GMP standards for marketing to developing countries.
  3. Domestic GMP, which has not been updated in line with current international standards and is intended to favour small and medium-scale industries.
  1. Three types of licences:
  2. a) Own manufacturing and marketing licence.
  3. b) Only marketing licence, with manufacturing outsourced under a loan licence.
  4. c) Third-party licence.

Consequently, the price of a particular medicine will vary with these three manufacturing standards and three types of licences.

Norway

All medicines are imported only if they meet cGMP manufacturing standards and have their own manufacturing licence.

3. India – DPCO market-based price

The formula is based on the average price of all brands with more than one per cent market share.

The incentive for the industry is to launch many brands at higher prices to increase the average. If there are 20 brands, the average price goes up and the ceiling price also increases.

The Supreme Court observed in 2013 that “DPCO incentivizes proliferation”.

Norway – Trinnpris

The prices of all medicines, irrespective of whether they are essential or non-essential, are controlled by comparing them with prices determined through the national-level tendering system.

Equity of access

Norway introduced Rural Availability Regulation 2023. According to this law, pharmaceutical companies must ensure that essential medicines are available in all regions, especially rural North Norway, and not just in the capital, Oslo.

Failure of Norway’s price control policy and lessons for India

Currently, a very specific problem is being faced in Sweden and Norway. It is not because the drugs do not work. It is because the drugs work too well and are too cheap.

Sweden and Norway are unique in that they have some of the lowest antibiotic resistance levels in Europe. Therefore, they still rely on old, narrow-spectrum penicillins such as phenoxymethylpenicillin (Penicillin V) and pivmecillinam as first-line treatments.

Phenoxymethylpenicillin is Norway’s most consumed antibiotic. However, these exact drugs are disappearing from the market.

The main reason is that the market is too small and too unprofitable. These are old, off-patent generics.

The second reason is dependence on external suppliers for essential medicines, as well as the vulnerability of supply chains in the event of economic or geopolitical crises.

Currently, up to 90 per cent of the antibiotics used globally are produced outside Europe, primarily in China and India. In India, some production also depends on chemical raw materials sourced from China.

Proposed model

To conclude, the current exorbitant and unaffordable prices of medicines in the Indian market can be controlled only if regulators think of a “Pro Public rather than Pro-Industry Policy”, based on the following principles:

  1. Proper selection of both essential and non-essential medicines: Selection should be based on “Real Health Needs” and not on “Artificial Market needs”. There should not be a dual price policy for these two classes.
  2. Price comparison: Price comparison should be with international manufacturing standards such as WHO-GMP and own licences, and not with outsourced manufacturing.
  3. Sustaining production capacity: While deciding the prices of essential medicines such as old antibiotics, low margins, unpredictable purchasing volumes and limited market opportunities should be considered positively for manufacturers. This will help them maintain and sustain their production capacity and invest in supply security.

The post Capitalism at the cost of healthcare appeared first on Express Pharma.

Apa Reaksi Anda?

Suka Suka 0
Kurang Suka Kurang Suka 0
Setuju Setuju 0
Tidak Setuju Tidak Setuju 0
Bagus  Bagus 0
Berguna Berguna 0
Hebat Hebat 0
Edusehat Platform Edukasi Online Untuk Komunitas Kesehatan Agar Mendapatkan Informasi Dan Pengetahuan Terbaru Tentang Kesehatan Dari Nasional Maupun Internasional. || An online education platform for the health community to obtain the latest information and knowledge about health from both national and international sources.